Kolexia
Farhat Hassan Yann Médecine générale
Farhat Hassan Yann
Médecine générale
Centre hospitalier de Versailles
Le Chesnay, France
62 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Leucémies Leucémie myéloïde Lymphome T Leucémie aigüe myéloïde Lymphome B Lymphome B diffus à grandes cellules Lymphome T périphérique Seconde tumeur primitive

Collaborateurs

Voir plus
Taksin-Bressot Anne-Laure
Taksin-Bressot Anne-Laure
Centre hospitalier de Versailles, Le Chesnay, France
Merabet Fatiha
Merabet Fatiha
Centre hospitalier de Versailles, Le Chesnay, France
Besson Caroline
Besson Caroline
Centre hospitalier de Versailles, Le Chesnay, France
Rousselot Philippe
Rousselot Philippe
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
A+A
10 collaboration(s)
Dernière en 2021
Amgen
9 collaboration(s)
Dernière en 2023
B3TSI
7 collaboration(s)
Dernière en 2023
Abbvie
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   16 février 2024
Study of Lacutamab in Peripheral T-cell Lymphoma: A Randomized Non Comparative Phase II Study of Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell Lymphoma
Essai Clinique (Innate Pharma)   04 décembre 2023
Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma: Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   09 janvier 2023
Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"
Annual Meeting Abstracts 2022   15 novembre 2022
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia.
Haematologica   01 juin 2022
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   14 janvier 2021
Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
Blood   05 novembre 2020
Role of endophytic Penicillium species and Pseudomonas monteilii in inducing the systemic resistance in okra against root rotting fungi and their effect on some physiochemical properties of okra fruit.
Journal of applied microbiology   30 octobre 2020
Highlights on the risk of pulmonary tuberculosis in patients on ibrutinib treatment: Case report and literature review.
EJHaem   19 septembre 2020
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
The Lancet. Oncology   15 janvier 2019